
    
      This study consists of the following:

        -  Screening period: 4 to 28-days

        -  Part A: a 12-week blinded, placebo controlled treatment period

        -  Part B: a 12-week blinded extension period

        -  Part C: an optional 52-week open-label extension period

        -  Part D: an additional optional 52-week open-label extension period

        -  Follow up period: 28 days
    
  